

JUL 30 2001

Please type a plus sign (+) inside this box →

PTO/SB/21-08400

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

2001

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/831,047
		Filing Date	May 3, 2001
		First Named Inventor	Magdalena Blaszczuk-Thurin
		Group Art Unit	
		Examiner Name	
Total Number of Pages in This Submission	7	Attorney Docket Number	WST93AUSA

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	2 pp. Letter
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2 pp. Form Pct/Do/EO/905
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	1 Diskette
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	HOWSON AND HOWSON Mary E. Bak
Signature	
Date	July 25, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 7-25-01

Typed or printed name	Lynn Brown
Signature	
Date	July 25, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270

PATENT TRADEMARK OFFICE

JUL 3 0 2001

WST93AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit:
Magdalena Blaszczyk-Thurin *et al*)
Appln. No.: 09/831047)
Filed: May 3, 2001)
For: COMPOSITIONS AND METHODS) July 25, 2001
FOR TREATMENT OF CANCER)

Assistant Commissioner for Patents
Washington, DC 20231
Attn: Shelby Vigil, Paralegal

LETTER


Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures in the above-identified application, dated June 15, 2001, attached please find:

- (a) the requested diskette, with the Sequence Listing in computer readable format as required by 37 CFR 1.821(e);
- (b) a copy of this Notice; and
- (c) a copy of the USPTO receipt-stamped postcard providing evidence that the diskette was originally filed with the application.

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on July 25, 2001.

Signature: 

Typed Printed Name: LYNN BROWN

In a telephone conference with Shelby Vigil, Applicant was advised that only the diskette was missing from the materials filed with the application on May 3, 2001.

The substitute computer readable diskette contains the same content as the paper copy of the Sequence Listing filed with the application on May 3, 2001. No new matter is contained on this diskette. Please enter this computer readable diskette into the application file. If further information is needed, the examiner or paralegal is requested to notify the undersigned at 215 540 9206.

The Director is hereby authorized to charge any deficiency or credit any overpayment in any fee due with this paper to our deposit account number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicant

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200

PATENT

Serial No.

Doc. No. US7934Atty/Sec MBS/DayDate 5-3-01Inventor Magdalena Bluszczuk-TamClient WSI/INTitle Compositions and Methods for Treatment of Cancer

The following has been received in the U S Patent and Trademark Office on the date stamped hereon

 26 pp. Spec. 725 Claims. 19 Abstract 4 pp. Declaration/Power of Attorney pp. Verified Statement (Small Entry) shts. Informal Drawings 5 shts. Formal Drawings (Eng 1-5) pp. Assignment 2 pp. Preliminary Amendment A pp. Extension of Time pp. Information Disclosure Statement
with PTO-1449 and referencesThe Patent and Trademark Office is respectfully requested to place its stamp on this postal card and place
it in the outgoing mail~~Express~~ ~~ETU33649102US~~ 3 pp. Transmittal Letter Issue Fee Notice of Appeal & Fee Check # 16536 for \$ 796.00 Check # 16537 for \$ 18.00 3 pg (1 and B) attach - Appendix A 36 pg Sequence List 1 pg. Statement 1 pg. Docket Copies of Request, Serial, & Written Respectfully, Opnum, 1st'l Prel. Exam HOWSON AND HOWSON

JC17 Rec'd PCT/PTO 03 MAY 2001

MBS



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
www.uspto.gov

JUL 30 2001

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831047	BLASZCZYK-THURIN	M WST93AUSA

HOWSON AND HOWSON
 ONE SPRING HOUSE CORPORATION CENTER
 BOX 457
 321 NORRISTOWN ROAD
 SPRING HOUSE, PA 19477

JUN 18 2001

INTERNATIONAL APPLICATION NO.

PCT/US99/26277

IA. FILING DATE	PRIORITY DATE
05 NOV 99	06 NOV 98

DATE MAILED

15 JUN 2001

ENTERED
DUE 8-15-01

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494) an Elected Office (37 CFR 1.495):

<input checked="" type="checkbox"/> U.S. Basic National Fee.	<input type="checkbox"/> Indication of Small Entity Status.
<input checked="" type="checkbox"/> Copy of the international application.	<input type="checkbox"/> Translation of the international application into English.
<input checked="" type="checkbox"/> Oath or Declaration of inventor(s).	<input type="checkbox"/> Translation of Article 19 amendments into English.
<input type="checkbox"/> Copy of Article 19 amendments.	<input type="checkbox"/> Other:
<input type="checkbox"/> Priority Document.	
<input type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any.	
<input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English.	

2. Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.

<input type="checkbox"/> U.S. Basic National Fee.	<input type="checkbox"/> Copy of the international application.
---	---

3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
- Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).

4. Additional claim fees of \$_____ as a large entity small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.

5. Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.

7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

A copy of this notice MUST be returned with this response.

Enclosed: PCT/DO/EO/917
 PTO-875

Notice of Defective Translation
 PCT/DO/EO/920

SHELBY VIGIL, PARALEG

Telephone: 703-305-3653

FORM PCT/DO/EO/905 (March 2001)

S.V.



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
09/831047	BLASZCZYK-THURIN	M WST93AUSA
INTERNATIONAL APPLICATION NO		
PCT/US99/26277		
1A. FILING DATE	PRIORITY DATE	
05 NOV 99	06 NOV 98	
DATE MAILED 15 JUN 2001		
DUE 8-15-01		

HOWSON AND HOWSON
ONE SPRING HOUSE CORPORATION CENTER
BOX 457
321 NORRISTOWN ROAD
SPRING HOUSE, PA 19477

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- Other: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

- (703) 308-4216, for Rules interpretation,
- (703) 308-4212, for CRF submission help,
- (703) 287-0200, for PatentIn software help.

SV
SHELBY VIGIL, PARALEG

Telephone: 703-305-3653